New York State Teachers Retirement System Sells 7,800 Shares of Haemonetics Corporation (NYSE:HAE)

New York State Teachers Retirement System lowered its stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 13.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,245 shares of the medical instruments supplier's stock after selling 7,800 shares during the quarter. New York State Teachers Retirement System owned 0.10% of Haemonetics worth $3,193,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Arizona State Retirement System grew its holdings in Haemonetics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after buying an additional 181 shares in the last quarter. CWC Advisors LLC. grew its holdings in Haemonetics by 7.4% during the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after buying an additional 212 shares in the last quarter. Vise Technologies Inc. grew its holdings in Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock worth $221,000 after buying an additional 225 shares in the last quarter. HighTower Advisors LLC grew its holdings in Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after buying an additional 244 shares in the last quarter. Finally, TD Waterhouse Canada Inc. bought a new stake in Haemonetics during the fourth quarter worth $25,000. Institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HAE shares. Raymond James Financial reissued a "strong-buy" rating and issued a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Baird R W raised Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Needham & Company LLC cut their price objective on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. JMP Securities reissued a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. Finally, Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $96.80.

Haemonetics Stock Down 2.4%

Shares of NYSE HAE opened at $75.00 on Tuesday. Haemonetics Corporation has a one year low of $55.30 and a one year high of $94.99. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The business's fifty day moving average price is $69.66 and its 200-day moving average price is $67.93. The stock has a market capitalization of $3.60 billion, a PE ratio of 22.66, a P/E/G ratio of 1.25 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. During the same quarter in the prior year, the firm earned $0.90 EPS. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. On average, equities research analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.